[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100642073":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":20,"locations":30,"responsibleParty":122,"collaborators":10,"id":126,"slug":127,"hasResults":128,"nctId":129,"briefTitle":130,"officialTitle":131,"acronym":132,"eligibilityCriteria":133,"healthyVolunteers":128,"sex":134,"minAge":135,"maxAge":136,"enrollmentInfo":137,"targetDuration":10,"studyType":140,"phases":10,"briefSummary":141,"conditions":142,"keywords":145,"overallStatus":81,"whyStopped":10,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":156},{"fullName":5,"class":6},"Eye & ENT Hospital of Fudan University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"T4 Sinonasal Adenoid Cystic Carcinoma: Surgery plus Postoperative Radiotherapy",null,"This single cohort includes patients with previously untreated T4 stage sinonasal adenoid cystic carcinoma (T4a or T4b, any N, M0 or M1 with stable limited lung metastases). All participants receive standard treatment as per routine clinical practice: radical surgery (aiming for R0\u002FR1 resection, via endoscopic, open, or combined approach) followed by postoperative intensity-modulated radiotherapy (IMRT) starting within 4-6 weeks after surgery. No experimental intervention is assigned. The cohort is followed prospectively for 3 years to assess progression-free survival, overall survival, local control, distant metastasis, treatment-related complications, and quality of life.",[13],"Procedure: Surgery",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"PROCEDURE","Surgery","Postoperative Radiotherapy",[9],[21,26],{"name":22,"role":23,"phone":24,"phoneExt":10,"email":25},"Quan Liu, MD","CONTACT","+86 15001959681","liuqent@163.com",{"name":27,"role":23,"phone":28,"phoneExt":10,"email":29},"Wanpeng Li, MD","+86 13262856870","18879117831@163.com",[31,50,65,80,92,107],{"facility":32,"status":33,"city":34,"state":35,"zip":36,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"The Second Affiliated Hospital of Harbin Medical University","NOT_YET_RECRUITING","Harbin","Heilongjiang","150001","China","CN",{"type":40,"coordinates":41},"Point",[42,43],126.65,45.75,{"lat":43,"lon":42},[46],{"name":47,"role":23,"phone":48,"phoneExt":10,"email":49},"Yanan Sun, MD","0451-86662962","h04015@hrbmu.edu.cn",{"facility":51,"status":33,"city":52,"state":53,"zip":54,"country":37,"countryCode":38,"cosmosGeoPoint":55,"geoPoint":59,"contacts":60},"Third Xiangya Hospital, Central South University","Changsha","Hunan","410013",{"type":40,"coordinates":56},[57,58],112.97087,28.19874,{"lat":58,"lon":57},[61],{"name":62,"role":23,"phone":63,"phoneExt":10,"email":64},"Guoling Tang, MD","0731-88638888","guolintan@csu.edu.cn",{"facility":66,"status":33,"city":67,"state":68,"zip":69,"country":37,"countryCode":38,"cosmosGeoPoint":70,"geoPoint":74,"contacts":75},"The First Affiliated Hospital of China Medical University","Shenyang","Liaoning","110001",{"type":40,"coordinates":71},[72,73],123.43278,41.79222,{"lat":73,"lon":72},[76],{"name":77,"role":23,"phone":78,"phoneExt":10,"email":79},"Hongquan Wei, MD","024-961200","hongquanwei@163.com",{"facility":5,"status":81,"city":82,"state":83,"zip":84,"country":37,"countryCode":38,"cosmosGeoPoint":85,"geoPoint":89,"contacts":90},"RECRUITING","Shanghai","Shanghai Municipality","200031",{"type":40,"coordinates":86},[87,88],121.45806,31.22222,{"lat":88,"lon":87},[91],{"name":22,"role":23,"phone":24,"phoneExt":10,"email":25},{"facility":93,"status":33,"city":94,"state":95,"zip":96,"country":37,"countryCode":38,"cosmosGeoPoint":97,"geoPoint":101,"contacts":102},"The First Affiliated Hospital of Air Force Medical University","Xi’an","Shanxi","710032",{"type":40,"coordinates":98},[99,100],113.52486,35.99785,{"lat":100,"lon":99},[103],{"name":104,"role":23,"phone":105,"phoneExt":10,"email":106},"Xiaodong Chen, MD","029-84775507","xdchen1981@139.com",{"facility":108,"status":33,"city":109,"state":110,"zip":111,"country":37,"countryCode":38,"cosmosGeoPoint":112,"geoPoint":116,"contacts":117},"The First Affiliated Hospital of Wenzhou Medical University","Wenzhou","Zhejiang","325000",{"type":40,"coordinates":113},[114,115],120.66682,27.99942,{"lat":115,"lon":114},[118],{"name":119,"role":23,"phone":120,"phoneExt":10,"email":121},"Kaiquan Zhu, MD","0577-55578167","kaiquanzhu@wzhospital.cn",{"type":123,"investigatorFullName":124,"investigatorTitle":125,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Quan Liu","Principal Investigator","100642073","surgery-plus-postoperative-radiotherapy-for-t4-sinonasal-adenoid-cystic-carcinoma-a-prospective-observational-study-100642073",false,"NCT07652489","Surgery Plus Postoperative Radiotherapy for T4 Sinonasal Adenoid Cystic Carcinoma: A Prospective Observational Study","SPORT-SNACC: A Prospective, Multicenter, Observational Cohort Study of Surgery Plus Postoperative Radiotherapy in T4 Sinonasal Adenoid Cystic Carcinoma","SPORT-SNACC","Inclusion Criteria:\n\n1. Age 18 80 years, any gender; ECOG performance status 0 2; life expectancy ≥6 months.\n2. Histologically confirmed primary sinonasal adenoid cystic carcinoma (cribriform, tubular, solid, or mixed type). Other malignancies excluded.\n3. T4 stage (T4a or T4b) according to AJCC 8th edition, based on contrast enhanced MRI\u002FCT.\n4. N0 2 (operable lymph node metastasis allowed).\n5. M0 (no distant metastasis on chest CT and abdominal ultrasound) OR M1 with stable limited lung metastases; (c) stable on two CT scans ≥3 months apart; (d) no respiratory symptoms.\n6. Previously untreated (no radiotherapy, chemotherapy, targeted therapy, immunotherapy, or tumor resection). MDT deems technically resectable (R0\u002FR1 achievable, not diffusely unresectable).\n7. Adequate organ function within 14 days before enrollment: ANC ≥1.5×10⁹\u002FL, platelets ≥100×10⁹\u002FL, Hb ≥90 g\u002FL; ALT\u002FAST ≤2.5×ULN, TBil ≤1.5×ULN, Cr ≤1.5×ULN or CrCl ≥50 mL\u002Fmin; LVEF ≥50%, no uncontrolled arrhythmia.\n8. Willing and able to provide written informed consent for clinical data collection (and optional biospecimen banking). Investigator judges good compliance.\n\nExclusion Criteria:\n\n1. Progressive lung metastases within 6 months (new lesions or \\>20% increase); extrapulmonary metastases (liver, bone, brain); symptomatic lung metastases.\n2. MDT judged unresectable, e.g., bilateral cavernous sinus invasion, brain parenchyma invasion, bilateral internal carotid artery encasement.\n3. Primary tumor outside sinonasal cavity (e.g., major salivary glands, oropharynx); non ACC histology.\n4. Other active malignancy within 5 years (except cured basal cell carcinoma, cervical carcinoma in situ, etc.).\n5. Severe comorbidities: NYHA class III\u002FIV heart failure, recent myocardial infarction or unstable angina, uncontrolled hypertension (≥160\u002F100 mmHg); COPD requiring home oxygen or interstitial lung disease; decompensated cirrhosis; active hepatitis B\u002FC without antiviral therapy; nephropathy requiring dialysis; active serious infection; active bleeding or coagulopathy (INR \\>1.5×ULN without anticoagulation, or platelets \\\u003C50×10⁹\u002FL).\n6. Special populations: pregnant or breastfeeding; unwilling to use contraception (if childbearing potential); severe allergy to medications required for surgery\u002Fradiotherapy; severe psychiatric or cognitive disorder impairing cooperation; currently participating in another interventional trial.\n7. Unable to undergo contrast enhanced MRI (metal implants, claustrophobia, gadolinium allergy); investigator judges inability to complete follow up (e.g., living abroad, substance abuse).","ALL","18 Years","80 Years",{"count":138,"type":139},70,"ESTIMATED","OBSERVATIONAL","This observational study follows patients with T4 stage sinonasal adenoid cystic carcinoma (a rare cancer of the nasal cavity\u002Fsinuses) who receive standard treatment: surgery followed by postoperative radiotherapy. The main goal is to measure the 3-year progression-free survival rate (the percentage of patients alive without cancer growth or spread). We will also assess overall survival, recurrence, side effects, and quality of life. This multicenter, prospective study will provide much-needed real-world data to improve patient counseling and guide future research.",[143,144],"Adenoid Cystic Carcinoma","Sinonasal Carcinoma",[146],"Carcinoma, Adenoid Cystic, Sinonasal, Radiotherapy, Adjuvant, Prospective Studies, Observational Study, Progression-Free Survival","2026-06-12",{"date":149,"type":150},"2026-06-17","ACTUAL",{"date":152,"type":139},"2026-06-01",{"date":154,"type":139},"2031-06-01",{"name":5,"class":6},6]